Evaxion to Unveil New Phase 2 Immune Data for Personalized Cancer Vaccine EVX-01 in October and November 2026Tip Ranks·1 day ago, 01:27 PMEVAX+0.63%
Evaxion to present new phase 2 immune data for EVX-01 melanoma vaccine at SITC 2026PUBT·1 day ago, 01:01 PMEVAX+0.63%
H.C. Wainwright Sticks to Its Buy Rating for Evaxion Biotech (EVAX)Tip Ranks·Sep 22 at 09:35 AMEVAX+0.63%
Evaxion expands AI-Immunology platform into autoimmune disease drug conceptsPUBT·Sep 14 at 12:00 PMEVAX+0.63%
Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS OfferingTip Ranks·Sep 4 at 11:28 AMEVAX+0.63%
From Regional Bank Mergers to Psychedelic Meds: Inside the Market's Unclassified CornersGlobal Report·Sep 1 at 11:32 AMEVAX+0.63%BNC-2.17%
Beyond the Aggregators: Value Chains in the Physical and Regulated EconomyGlobal Report·Sep 1 at 09:18 AMUNP+2.15%CMI+2.19%
The Ultimate Leverage Game in AI Hardware: Moving Beyond NvidiaGlobal Report·Aug 30 at 11:34 AMSKHY+0.84%EVAX+0.63%
Biotech Bingo: Evaxion's AI Gamble and a Laser ETF Masquerading as PharmaGlobal Report·Aug 30 at 09:16 AMEVAX+0.63%
Evaxion releases transcript of Q2 2026 business update and financial results callPUBT·Aug 21 at 10:58 AMEVAX+0.63%
Evaxion Biotech: Strong R&D progress and financial discipline support a cash runway into H2 2027Quartr·Aug 20 at 11:48 PMEVAX+0.63%
Evaxion (EVAX) Q2 2026 Earnings Call: $14M Cash and EVX-01 UpdateTradingKey·Aug 20 at 08:02 PMEVAX+0.63%
Evaxion Biotech Q2 2026 Earnings Call: Complete Transcriptbenzinga_article·Aug 20 at 01:34 PMEVAX+0.63%
